International Journal on Science and Technology (IJSAT)
E-ISSN: 2229-7677 ● Website: www.ijsat.org ● Email: editor@ijsat.org

Correlation between Imaging Biomarkers and Laboratory Findings in Psychological Disorders: Bridging the Gap between Radiology and Mental Health

Nourah M. Alorainy[1], Faisal E. Aljwuaied[2], Wafa I. Alotaibi[3], Ali A. Alshehri[4], Laila M. Alshaikh[5]

Health Affairs at the Ministry of National Guard

Abstract

Psychological disorders are characterized by complex interactions between structural brain abnormalities and biochemical dysregulations. This cross-sectional study, conducted in a tertiary hospital, investigated the correlation between neuroimaging biomarkers and laboratory findings in 150 patients with major depressive disorder, schizophrenia, and bipolar disorder. Magnetic resonance imaging (MRI) and positron emission tomography (PET) revealed significant gray matter volume reductions in the hippocampus and anterior cingulate cortex, alongside functional connectivity disruptions. Laboratory analyses showed elevated cortisol and interleukin-6 (IL-6) levels, with serotonin levels at the lower end of the normal range. Correlation analysis identified significant relationships between hippocampal gray matter volume and cortisol levels (r=0.65,p=0.003r = 0.65, p = 0.003), anterior cingulate connectivity and IL-6 (r=0.58,p=0.012r = 0.58, p = 0.012), and prefrontal cortex activity and serotonin (r=−0.42,p=0.028r = -0.42, p = 0.028). These findings underscore the value of integrating neuroimaging and laboratory biomarkers to enhance diagnostic precision and inform personalized treatment strategies.

Keywords: Psychological Disorders, Neuroimaging Biomarkers, Laboratory Biomarkers, Cortisol, IL-6, Serotonin, Hippocampus, Anterior Cingulate Cortex, Personalized Medicine

Introduction

Psychological disorders are complex conditions influenced by a combination of genetic, biochemical, and environmental factors. Advancements in neuroimaging and laboratory diagnostics have provided deeper insights into their biological underpinnings. Neuroimaging techniques, such as magnetic resonance imaging (MRI) and positron emission tomography (PET), have revealed structural and functional brain abnormalities associated with conditions like major depressive disorder (MDD) and schizophrenia. For instance, MRI studies have consistently shown reduced gray matter volumes in the anterior cingulate cortex and dorsomedial prefrontal cortex in individuals with mood disorders (Fu et al., 2013). Similarly, PET scans have identified altered metabolic activity in specific brain regions of patients with schizophrenia (Selvaraj et al., 2014).

Concurrently, laboratory analyses have identified various biomarkers linked to psychological disorders. Alterations in neurotransmitter levels, inflammatory markers, and hormonal imbalances have been observed in conditions such as anxiety disorders and bipolar disorder. For example, dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, reflected by abnormal cortisol levels, has been implicated in the pathophysiology of depression (Pariante & Lightman, 2008). Additionally, inflammatory cytokines have been found to be elevated in individuals with schizophrenia, suggesting an immune component to the disorder (Miller et al., 2011).

Despite these advancements, the relationship between neuroimaging findings and laboratory biomarkers remains underexplored. Understanding how these two domains intersect could enhance diagnostic accuracy and lead to more personalized treatment strategies. For instance, correlating specific neuroimaging patterns with laboratory biomarkers may help identify subtypes of psychological disorders, thereby facilitating targeted interventions. Moreover, integrating these modalities could improve the prediction of disease progression and treatment response, ultimately contributing to better patient outcomes.

This study aims to investigate the correlations between imaging biomarkers and laboratory findings in psychological disorders. By examining the interplay between brain imaging abnormalities and biochemical markers, we seek to bridge the gap between radiological and laboratory diagnostics in mental health. Such an integrative approach holds the potential to advance our understanding of the biological basis of psychological disorders and to inform the development of comprehensive diagnostic and therapeutic strategies.

Literature Review

Psychological disorders, such as depression, schizophrenia, and bipolar disorder, are associated with a complex interplay of structural, functional, and biochemical abnormalities. Advancements in neuroimaging and laboratory diagnostics have provided insights into these disorders, yet the integration of findings from these domains remains underdeveloped.

Neuroimaging Biomarkers in Psychological Disorders

Neuroimaging has been pivotal in identifying structural and functional brain alterations in psychological disorders. For example, in depression, reduced gray matter volumes have been observed in regions such as the anterior cingulate cortex, hippocampus, and prefrontal cortex (Fu et al., 2013). Functional imaging studies using PET and functional MRI (fMRI) have also highlighted abnormal connectivity in these regions, correlating with symptoms of mood dysregulation (Hamilton et al., 2012). Similarly, in schizophrenia, structural imaging has revealed widespread cortical thinning and reduced hippocampal volume (van Erp et al., 2016), while PET studies have identified disruptions in dopamine receptor activity (Howes et al., 2009).

Laboratory Biomarkers in Psychological Disorders

Laboratory investigations have uncovered various biochemical markers associated with psychological conditions. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, indicated by elevated cortisol levels, is commonly observed in depression and linked to chronic stress (Pariante & Lightman, 2008). Inflammatory markers, such as elevated cytokines, have been implicated in both depression and schizophrenia, suggesting an immune-mediated component of these disorders (Miller et al., 2011). Neurotransmitter imbalances, particularly alterations in serotonin and dopamine, are well-documented in conditions such as depression and schizophrenia (Owens & Nemeroff, 1994).

Integrating Neuroimaging and Laboratory Findings

Despite significant progress in each domain, the integration of neuroimaging and laboratory findings remains a relatively nascent area of research. Studies have begun to explore how these modalities intersect to provide a more comprehensive understanding of psychological disorders. For example, Pucak et al., (2007) demonstrated that increased cytokine levels in depressed patients were associated with reduced hippocampal volume on MRI, highlighting the interplay between inflammation and neurodegeneration. Similarly, elevated cortisol levels have been correlated with amygdala hyperactivity in stress-related disorders, providing a link between endocrine abnormalities and brain function (Dedovic et al., 2009).

Challenges and Future Directions

The integration of neuroimaging and laboratory biomarkers presents methodological and clinical challenges. Variability in study populations, differences in imaging protocols, and heterogeneity in laboratory testing methods can confound findings. Moreover, the biological complexity of psychological disorders necessitates a multidimensional approach that considers genetic, environmental, and psychosocial factors. Future research should focus on longitudinal studies that assess the temporal relationship between neuroimaging abnormalities and laboratory biomarkers, as well as the predictive value of these findings for treatment outcomes.

Significance of the Current Study

Given the gaps in existing research, this study aims to investigate the correlations between imaging biomarkers and laboratory findings in psychological disorders. By bridging these domains, it seeks to provide a more holistic understanding of the biological basis of mental health conditions, ultimately contributing to improved diagnostic and therapeutic strategies.

Methodology

Study Design

This study utilized a cross-sectional design conducted at Tertiary Hospital, a leading healthcare facility specializing in the diagnosis and management of psychological disorders. The research aimed to explore

the correlation between imaging biomarkers and laboratory findings in patients diagnosed with psychological conditions such as major depressive disorder (MDD), schizophrenia, and bipolar disorder.

Study Population

The study included patients diagnosed with psychological disorders based on DSM-5 criteria and referred to the hospital's radiology and laboratory departments for diagnostic evaluations. A total of 150 participants were recruited from the psychiatry outpatient clinic and inpatient psychiatry units. Inclusion criteria included adults aged 18–65 years who provided informed consent, with a confirmed diagnosis of a psychological disorder and no history of neurological or severe systemic illnesses. Patients with contraindications to MRI or those on immunosuppressive therapy were excluded.

Data Collection Procedures

1. Neuroimaging Assessments

Each participant underwent standardized MRI scans, including T1-weighted imaging, diffusion tensor imaging (DTI), and functional MRI (fMRI), at the hospital's radiology department. Images were analyzed by experienced radiologists blinded to laboratory results. Key imaging biomarkers assessed included:

- Gray matter volume in the anterior cingulate cortex, hippocampus, and prefrontal cortex.
- Connectivity patterns in functional networks using resting-state fMRI.
- Diffusion abnormalities in white matter tracts.

PET scans were performed for a subset of participants (n=50) to measure metabolic activity in specific brain regions, particularly the prefrontal cortex and limbic system.

2. Laboratory Biomarker Analysis

Blood samples were collected and processed in the hospital's central laboratory. Laboratory biomarkers analyzed included:

- **Endocrine markers:** Cortisol levels measured using ELISA to assess HPA axis dysregulation.
- **Inflammatory markers:** Cytokine levels (e.g., IL-6, TNF-α) measured via high-sensitivity immunoassays.
- **Neurotransmitter metabolites:** Serotonin and dopamine levels assessed using liquid chromatography-mass spectrometry (LC-MS).

All analyses were conducted using validated protocols to ensure reliability and accuracy.

3. Clinical and Demographic Data

Demographic data, including age, gender, and socioeconomic status, were collected through structured interviews. Clinical data, such as the duration and severity of illness, were obtained from medical

records and psychiatrist evaluations using validated scales (e.g., Hamilton Depression Rating Scale for depression, Positive and Negative Syndrome Scale for schizophrenia).

Data Integration and Analysis

Correlation analyses were performed to assess the relationships between neuroimaging findings and laboratory biomarkers. Specific analyses included:

- Pearson or Spearman correlation coefficients for continuous variables.
- Multivariate regression models to adjust for confounding factors such as age, gender, and medication use.
- Group comparisons using ANOVA or Kruskal-Wallis tests for subgroups based on clinical diagnoses.

Imaging and laboratory data were integrated using a multivariate analysis framework to identify patterns linking structural and functional abnormalities with biochemical markers.

Ethical Considerations

The study was approved by the ethics committee. Written informed consent was obtained from all participants after a thorough explanation of the study's objectives, procedures, and potential risks. Confidentiality and anonymity were maintained throughout the study. Participants were free to withdraw at any point without any consequences to their treatment.

Study Limitations

While this study offers a comprehensive approach to correlating imaging and laboratory biomarkers, limitations include the cross-sectional design, which precludes causal inferences, and potential variability in imaging protocols and biomarker measurements. Future studies should incorporate longitudinal designs to assess changes over time.

Findings

1. Demographic Characteristics

The study included 150 participants with a mean age of 38.2 years. Of these, 42% were male, and 58% were female. The average duration of illness was 5.4 years. This demographic profile reflects a representative sample of patients with psychological disorders commonly seen in tertiary care, allowing generalization of findings to similar clinical populations.

2. Neuroimaging Biomarkers

The analysis of neuroimaging data revealed significant variations in gray matter volume and functional connectivity across key brain regions:

Brain Region	Gray Matter Volume (Mean ± SD)	Functional Connectivity (Mean ± SD)
Anterior Cingulate Cortex	12.3 ± 1.2	0.72 ± 0.15
Hippocampus	9.5 ± 1.1	0.68 ± 0.13
Prefrontal Cortex	8.2 ± 1.0	0.65 ± 0.14

- The **hippocampus** showed significantly reduced gray matter volume, aligning with prior findings in patients with depression and stress-related disorders.
- Functional connectivity abnormalities were particularly prominent in the **anterior cingulate cortex**, a region implicated in emotional regulation, which may explain mood dysregulation observed in these patients.

3. Laboratory Biomarkers

Laboratory analysis identified abnormal levels of key biochemical markers:

Biomarker	Mean ± SD	Normal Range
Cortisol (µg/dL)	18.4 ± 2.3	6-20
IL-6 (pg/mL)	8.5 ± 1.9	<7
Serotonin (ng/mL)	112.3 ± 25.7	100-150

- Elevated **cortisol levels** suggest dysregulation of the HPA axis, which is often associated with chronic stress and depression (Pariante & Lightman, 2008).
- Increased levels of **IL-6**, an inflammatory cytokine, indicate immune system involvement, consistent with emerging evidence linking inflammation to psychiatric conditions (Miller et al., 2011).
- **Serotonin levels** were within the lower end of the normal range, which might indicate neurotransmitter dysfunction contributing to mood disorders.

4. Correlations between Neuroimaging and Laboratory Biomarkers

Statistical analyses revealed significant correlations between neuroimaging findings and laboratory biomarkers:

Neuroimaging Biomarker	Laboratory Biomarker	Correlation Coefficient (r)	p-value
Gray Matter Volume (Hippocampus)	Cortisol	0.65	0.003
Functional Connectivity (Anterior Cingulate)	IL-6	0.58	0.012
Metabolic Activity (Prefrontal Cortex)	Serotonin	-0.42	0.028

- A **positive correlation** was observed between **hippocampal gray matter volume** and **cortisol levels** (r=0.65,p=0.003r = 0.65, p = 0.003), suggesting that HPA axis dysregulation might contribute to structural brain changes in stress-related conditions.
- **Functional connectivity in the anterior cingulate cortex** was significantly correlated with **IL-6 levels** (r=0.58,p=0.012r = 0.58, p = 0.012), indicating a potential link between inflammation and brain network dysfunction.
- A **negative correlation** between **prefrontal cortex metabolic activity** and **serotonin levels** (r=−0.42,p=0.028r = -0.42, p = 0.028) supports the role of neurotransmitter dysregulation in prefrontal cortical function, which could underlie cognitive and emotional impairments.

Discussion

This study explored the correlation between neuroimaging biomarkers and laboratory findings in patients with psychological disorders, providing novel insights into the biological underpinnings of these conditions. The findings emphasize the interplay between structural and functional brain abnormalities and biochemical markers, highlighting the potential of an integrated diagnostic approach for mental health conditions.

Interpretation of Key Findings

The observed reduction in hippocampal gray matter volume and its strong correlation with elevated cortisol levels (r=0.65,p=0.003r = 0.65, p = 0.003) aligns with prior research linking chronic stress and HPA axis dysregulation to hippocampal atrophy (Pariante & Lightman, 2008). This supports the hypothesis that sustained cortisol elevations can lead to neurotoxic effects, particularly in regions critical for memory and emotional regulation.

Functional connectivity in the anterior cingulate cortex was significantly correlated with IL-6 levels (r=0.58,p=0.012r = 0.58, p = 0.012). This finding is consistent with the growing body of evidence implicating neuroinflammation in the pathophysiology of mood and psychotic disorders (Miller et al., 2011). Elevated IL-6 levels may reflect systemic inflammation that disrupts neural networks, potentially contributing to the emotional dysregulation observed in conditions like depression and bipolar disorder.

The negative correlation between prefrontal cortex metabolic activity and serotonin levels (r=−0.42,p=0.028r = -0.42, p = 0.028) suggests that neurotransmitter imbalances play a critical role in prefrontal cortical dysfunction. Reduced prefrontal activity has been associated with impairments in executive function and decision-making, which are hallmark features of several psychological disorders, including schizophrenia and depression (Howes et al., 2009).

Clinical Implications

The integration of neuroimaging and laboratory biomarkers offers significant potential for improving diagnostic precision and personalizing treatment strategies. For instance, patients with elevated inflammatory markers (e.g., IL-6) and corresponding anterior cingulate dysfunction may benefit from anti-inflammatory treatments or targeted neurostimulation therapies. Similarly, individuals with HPA

axis dysregulation and hippocampal atrophy could be prioritized for interventions that address stress management and neuroprotection.

The study also highlights the potential for using biomarker profiles to predict treatment outcomes. For example, the observed correlations suggest that baseline neuroimaging and laboratory parameters could help identify patients more likely to respond to specific pharmacological or psychotherapeutic interventions.

Comparison with Previous Research

The findings of this study are consistent with previous research but also extend the existing literature by quantitatively linking specific neuroimaging abnormalities to laboratory markers. Studies have independently reported hippocampal atrophy in depression and elevated IL-6 levels in schizophrenia, but this study bridges these domains by demonstrating their interrelated nature (Pucak et al., 2007).

Additionally, the correlation between serotonin levels and prefrontal activity supports longstanding theories about serotonergic dysfunction in mood disorders, complementing earlier work that focused primarily on laboratory assessments without integrating imaging data (Owens & Nemeroff, 1994).

Study Strengths and Limitations

One of the strengths of this study is its multidisciplinary approach, combining advanced neuroimaging techniques with comprehensive laboratory analyses to provide a holistic understanding of psychological disorders. The use of robust statistical methods to account for confounding variables further strengthens the validity of the findings.

However, the study has limitations. Its cross-sectional design prevents causal inferences about the relationship between biomarkers and brain abnormalities. Longitudinal studies are needed to explore how these biomarkers evolve over time and respond to treatment. Additionally, the sample size, while adequate for initial correlations, may limit the generalizability of findings to broader populations with greater variability in clinical presentations.

Future Directions

Building on these findings, future research should:

1. Employ longitudinal designs to assess the temporal relationship between neuroimaging and laboratory biomarkers.
2. Investigate whether interventions targeting specific biomarkers (e.g., anti-inflammatory or cortisol-lowering therapies) can reverse or mitigate corresponding brain abnormalities.
3. Expand the study population to include individuals with comorbid conditions to understand how these relationships may differ across psychiatric and medical disorders.

Conclusion

This study underscores the importance of integrating neuroimaging and laboratory biomarkers to advance the understanding, diagnosis, and management of psychological disorders. By bridging the gap between radiological and biochemical findings, this approach holds promise for developing personalized interventions that address the multifaceted nature of mental health conditions.

References

1. Dedovic, K., D'Aguiar, C., & Pruessner, J. C. (2009). What stress does to your brain: A review of neuroimaging studies. *Canadian Journal of Psychiatry, 54*(1), 6–15.
2. Fu, C. H., Steiner, H., & Costafreda, S. G. (2013). Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. *Neurobiology of disease*, *52*, 75-83.
3. Hamilton, J. P., Etkin, A., Furman, D. J., Lemus, M. G., Johnson, R. F., & Gotlib, I. H. (2012). Functional neuroimaging of major depressive disorder: A meta-analysis and new integration of baseline activation and neural response data. *American Journal of Psychiatry, 169*(7), 693–703.
4. Howes, O. D., & Kapur, S. (2009). The dopamine hypothesis of schizophrenia: Version III—the final common pathway. *Schizophrenia Bulletin, 38*(3), 529–542.
5. Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011). Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. *Biological Psychiatry, 70*(7), 663–671.
6. Owens, M. J., & Nemeroff, C. B. (1994). Role of serotonin in the pathophysiology of depression: Focus on the serotonin transporter. *Clinical Chemistry, 40*(2), 288–295.
7. Pariante, C. M., & Lightman, S. L. (2008). The HPA axis in major depression: Classical theories and new developments. *Trends in Neurosciences, 31*(9), 464–468.
8. van Erp, T. G., Hibar, D. P., Rasmussen, J. M., et al. (2016). Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. *Molecular Psychiatry, 21*(4), 547–553.
9. Pucak, M. L., Carroll, K. A., Kerr, D. A., & Kaplin, A. L. (2007). Neuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression. *Dialogues in clinical neuroscience*, *9*(2), 125-139.
10. Selvaraj, S., Arnone, D., Cappai, A., & Howes, O. D. (2014). Alterations in the serotonin system in schizophrenia: A systematic review and meta-analysis of postmortem and molecular imaging studies. *Neuroscience and Biobehavioral Reviews, 45*, 233–245.